Report: COVID-19 patients are responding quickly to experimental drug remdesivir
In Chicago, COVID-19 coronavirus patients participating in a clinical study of the antiviral medicine remdesivir are experiencing quick recoveries from their respiratory and fever symptoms, Stat News reported Thursday.
Remdesivir was developed by Gilead Sciences to treat Ebola. The company is conducting two global studies — the severe COVID-19 study includes 2,400 patients at 152 trial sites, and the moderate COVID-19 study has 1,600 patients at 169 sites. The trials are investigating five- and 10-day treatment courses of remdesivir, and aim to have a statistical comparison of improvement between them.
University of Chicago Medicine is one of the hospitals participating, with 125 COVID-19 patients — 113 of them with severe symptoms — taking part in two Phase 3 clinical trials, receiving daily infusions of remdesivir. Stat has obtained video of Kathleen Mullane, the University of Chicago's infectious disease specialist who is overseeing the studies, sharing with her colleagues updates on the trials, including how nearly all of the patients have been discharged in less than a week.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Only two patients have died, she said, and when the drug is started, "we see fever curves falling." Mullane also shared that people have "come off ventilators a day after starting therapy. So, in that realm, overall our patients have done very well." Most patients leave the hospital after six days, she added, "so that tells us duration of therapy doesn't have to be 10 days. We have very few that went out to 10 days, maybe three."
The hospital's trials do not include a placebo group, and Stat notes that it is "impossible to determine the full study results with any certainty. Still, no other clinical data from the Gilead studies have been released to date, and excitement is high." Read more at Stat News.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Catherine Garcia is night editor for TheWeek.com. Her writing and reporting has appeared in Entertainment Weekly and EW.com, The New York Times, The Book of Jezebel, and other publications. A Southern California native, Catherine is a graduate of the University of Redlands and the Columbia University Graduate School of Journalism.
-
Katespiracy: is the media to blame?
Talking Point Public statement about cancer diagnosis followed weeks of wild speculation and conspiracy theories
By Julia O'Driscoll, The Week UK Published
-
'Restoring life to an ancient watershed'
Today's Newspapers A roundup of the headlines from the US front pages
By The Week Staff Published
-
Crossword: March 26, 2024
The Week's daily crossword
By The Week Staff Published
-
US bans final type of asbestos
Speed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
By Peter Weber, The Week US Published
-
Seattle Children's Hospital sues Texas over 'sham' demand for transgender medical records
Speed Read Texas Attorney General Ken Paxton subpoenaed records of any Texan who received gender-affirming care at the Washington hospital
By Peter Weber, The Week US Published
-
Afghanistan has a growing female suicide problem
Speed Read The Taliban has steadily whittled away women's and girls' rights in Afghanistan over the past 2 years, prompting a surge in depression and suicide
By Peter Weber, The Week US Published
-
US life expectancy rose in 2022 but not to pre-pandemic levels
Speed Read Life expectancy is slowly crawling back up
By Devika Rao, The Week US Published
-
Vallance diaries: Boris Johnson 'bamboozled' by Covid science
Speed Read Then PM struggled to get his head around key terms and stats, chief scientific advisor claims
By The Week UK Published
-
An increasing number of dog owners are 'vaccine hesitant' about rabies
Speed Read A new survey points to canine vaccine hesitancy
By Devika Rao, The Week US Published
-
Anger may be a powerful motivator for tough goals, new study suggests
Speed Read Keeping your cool might actually be less efficient than letting your anger drive you
By Theara Coleman, The Week US Published
-
A tropical skin disease is making the rounds in the US
Speed Read Leishmaniasis is endemic to the country and can cause ulcers and disfiguration
By Devika Rao, The Week US Published